https://novaliq.com

Home - NovaliqNovaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products.Home - Novaliq Skip to main content Our Technology EyeSol® Novel Drug Product Development Chemistry Manufacturing Control (CMC) Disease Areas & Pipeline Pipeline Dry Eye Disease Glaucoma Dermatology Diabetic Retinopathy Products CyclASol® NOV03 (perfluorohexyloctane) BTQ 1902 Novatears® (perfluorohexyloctane) Novatears®+Omega-3 News & Media Company Presentation Press Releases Publications About us Management Supervisory Board Our Partners Contact Novaliq in USA Careers Investor Relation Our Technology EyeSol® Novel Drug Product Development Chemistry Manufacturing Control (CMC) Disease Areas & Pipeline Pipeline Dry Eye Disease Glaucoma Dermatology Diabetic Retinopathy Products CyclASol® NOV03 (perfluorohexyloctane) BTQ 1902 Novatears® (perfluorohexyloctane) Novatears®+Omega-3 News & Media Company Presentation Press Releases Publications About us Management Supervisory Board Our Partners Contact Novaliq in USA Careers Investor Relation Revolutionize the treatment paradigm for Diabetic Retinopathy R&D program with distinct and novel drug candidates with relevant modes-of-action in the diabetic retinopathy pathophysiology. Diabetic Retinopathy Novaliq Transforms Ophthalmic Topical Therapies Our unique and versatile water-free technology revolutionizes ocular therapies. ABOUT US EyeSol® is a novel drug category of drugs Our products are beneficial for the ocular surface, micro-dosed and non-preserved targeting multiple ophthalmic diseases with a “smart” eye drop. Products Overcoming Limitations in Eye Care Therapies Our technology, opens completely new and exciting opportunities in the eye care for the relief and prevention of ophthalmological diseases in various indications for patients. EyeSol We revolutionize dry eye drug therapies Two new and distinct drug products approved in Dry Eye Disease by the US FDA in 2023. Dry Eye Disease We are Pioneers Our team of seasoned industry experts explores the world of water-free therapies to develop best-in-class ocular therapies. We expand into other eye care indications and topical therapeutics spaces. Team Novel Drug Products Creation with new composition-of-matter IP EyeSol® Innovation generates Novel IP until at least. Novel Product Creation Revolutionize the treatment paradigm for Diabetic Retinopathy Novaliq Transforms Ophthalmic Topical Therapies EyeSol® is a novel drug category of drugs Overcoming Limitations in Eye Care Therapies We revolutionize dry eye drug therapies We are Pioneers Novel Drug Products Creation with new composition-of-matter IP Technology EyeSol® is a novel drug category of water-free therapies See More EyeSol® About Dry Eye Disease Novel Drug Product Creation Substances Used Disease Areas & Pipeline Novaliq offers an industry-leading portfolio of topical drug products that are water-free. See More Diabetic Retinopathy Program Dermatology Dry Eye Disease Glaucoma Novaliq products NovaTears® NovaTears® is the first water-free eye drop based on EyeSol® developed for the treatment of dry eye. NovaTears® is CE certified since 2013 and successfully commercialized in Europe and in Australia/New Zealand by our partners. read more NovaTears®+Omega-3 NovaTears®+Omega-3 is the first eye drop containing high dose of Omega-3 fatty acids (0,2%). read more Lead product candidates Our late-stage investigational drug developments provide unique therapeutic options for millions of diagnosed but untreated or undertreated dry eye patients: CyclASol® CyclASol® has the potential to change the way eye care practitioners treat patients with dry eye disease read more NOV03 Is the first drug with novel mechanism of action developed to treat the signs and symptoms of evaporative dry eye disease read more News & Media Reach more about our latest press releases, key scientificpublications and other company resources Company Presentation Transforms Ocular Therapeutics Latest Publication Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial Latest Press Release Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye (Ciclosporin 0.1% Eye Drops Solution) Novaliq is a private biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free ophthalmic technology. About us © Novaliq GmbH | Realization: formativ.net GmbH Imprint Data Privacy / Datenschutz Cookie Policy Terms and Conditionsenusen-US1728750421https://novaliq.com

تعديل موقعك؟

ماذا تفعل؟